US Edition
Semaglutide Improves Liver Function Independently of Weight Loss
Canadian researchers found semaglutide improved liver inflammation and scarring in mice, even when brain appetite receptors were absent.
- Canadian researchers found that Ozempic and Wegovy improve liver health independently of weight loss, according to a study published in Cell Metabolism revealing GLP-1 medicines act directly on specific liver cells.
- MASH affects about 25% of Canadian adults and is closely linked with obesity and Type 2 diabetes; for years, scientists puzzled over how GLP-1 medicines improved organ function without explaining the direct mechanism.
- Postdoctoral fellow Maria Gonzalez-Rellan identified that LSECs carry receptors for these therapies. Although LSECs account for only around 3% of liver cell volume, they orchestrate anti-inflammatory molecules that calm the liver environment.
- Study lead author Daniel Drucker noted patients see liver improvements even when losing very little weight. "But we now know that weight shouldn't be the only measure of success," Drucker added.
- These findings challenge long-held assumptions about how GLP-1 medicines work in the liver. Knowing semaglutide improves liver health independently of weight loss could influence prescribing decisions for physicians treating metabolic liver disease.
16 Articles
16 Articles
Semaglutide improves liver function independently of weight loss
Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.
ABC FOX Montana
Weight loss drugs like Ozempic also improve liver health
A new study found GLP-1 drugs improve liver health by targeting specialized blood vessel cells in the liver.
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
Studying mice, researchers at Toronto’s Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve organ function, and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease. Headed by Daniel Druc…
Coverage Details
Bias Distribution
- 63% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
